Newspaper Publication of Audited Financial Results as on 31st March, 2026.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported strong Q4 FY26 results with consolidated net profit after tax of ₹202.70 crore, up 29% from ₹156.89 crore in Q4 FY25. Full year FY26 consolidated net profit came in at ₹674.77 crore on total income of ₹7,344.90 crore. On a standalone basis, Q4 profit after tax surged over 200% to ₹243.07 crore versus ₹75.34 crore, driven by a 116% jump in profit before exceptional items to ₹198.21 crore. The company had exceptional items during the year that reduced pre-tax profit but benefited after-tax figures. EPS for FY26 stood at ₹34.33 per share.
The sharp recovery in standalone Q4 profitability and strong full-year performance indicates operational improvement and likely cost management. The exceptional items worth watching suggest one-time items impacted comparisons. Positive signal for shareholders ahead of potential dividend announcements.